Categories: News

Arbutus to Participate at Jefferies London Healthcare Conference

WARMINSTER, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different modes of action to provide a cure for people with chronic hepatitis B virus (HBV) infection and to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the Jefferies London Healthcare Conference.

Presenters:
William Collier, President and Chief Executive Officer; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer

A webcast of the virtual fireside chat will be available beginning on Thursday, November 18, 2021 at 8:00 am GMT / 3:00 am ET, and can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com. An archived replay of the webcast will be available on the Company’s website after the conference.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different modes of action to provide a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that suppress viral replication, reduce surface antigen and reawaken the immune system. Arbutus believes this three-prong approach is key to transforming the treatment and developing a potential cure for chronic HBV infection. Arbutus’ HBV product pipeline includes RNA interference (RNAi) therapeutics, oral capsid inhibitors, oral compounds that inhibit PD-L1 and oral HBV RNA destabilizers. In addition, Arbutus has an ongoing drug discovery and development program directed to identifying orally active agents for treating coronaviruses (including COVID-19). For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com

Staff

Recent Posts

PMI Foods Donates 5,000 Pounds of Prime Ribs to City of Refuge to Help Victims of Human Trafficking

SALT LAKE CITY, July 15, 2024 /PRNewswire/ -- Parker Migliorini International (PMI Foods) just announced a…

3 hours ago

PausePoint Helps Employees and Professionals Prioritize Mental Health

PausePoint, a new mindfulness and wellbeing app designed to help professionals reclaim time, launches officially.…

3 hours ago

CareMagnus Bridges the Gaps in Multi-Channel Care

CareMagnus enhances the multi-channel and person-centred care continuum with its intelligent care management cloud platform.…

3 hours ago

Pharmaceutical Quality Management Systems Market to Be Worth $4.59 Billion by 2031 – Exclusive Report by Meticulous Research®

REDDING, Calif., July 15, 2024 /PRNewswire/ -- According to a new market research report titled, 'Pharmaceutical…

3 hours ago

Electrosurgical Devices Market to Reach USD 10.4 Billion by 2034, Fueled by Advanced Technology Ensuring Precision and Safety | Transparency Market Research

The rise in minimally invasive surgeries is a key driver for the global electrosurgical devices market…

3 hours ago